Ocular onchocerciasis: Current management and future prospects

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1479-1491

  Babalola, Olufemi Emmanuel ^a  

^a BINGHAM UNIVERSITY   (Nigeria)

Author keywords

Management; Ocular; Onchocerciasis; River blindness

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; AVERMECTIN; AVERMECTIN C22; AVERMECTIN C23; CHLORPHENOTANE; CORTICOSTEROID; DIETHYLCARBAMAZINE; DIHYDROAVERMECTIN B1; DOXYCYCLINE; FLUBENDAZOLE; IVERMECTIN; MILBEMYCIN; MOXIDECTIN; NEMADECTIN; PLACEBO; SURAMIN; TEMEFOS; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADRENAL CORTEX DISEASE; ANTHELMINTIC ACTIVITY; ARTHRALGIA; BONE MARROW TOXICITY; BRAIN DISEASE; COMMUNITY CARE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; EXFOLIATIVE DERMATITIS; EYE SURGERY; HUMAN; HYPOTENSION; KERATITIS; KIDNEY INJURY; LIVER TOXICITY; LOIASIS; LYMPHADENOPATHY; MAZZOTTI REACTION; NAUSEA; NEMATODIASIS; NONHUMAN; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OPTIC NEURITIS; PARASITE CONTROL; PARASITE PREVALENCE; PARASITE TRANSMISSION; REVIEW; SIMULIIDAE; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TINGLING; STEVENS JOHNSON SYNDROME; TACHYCARDIA; URTICARIA; VECTOR CONTROL; VOMITING;

EID: 81155139126     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s8372     Document Type: Review

References (101)

1. Duke BO. The Epidemiology of Eye Disease. 2nd ed. Johnson JJ, editor. London, UK: Arnold Hodder Headline Group; 2003:288-305.
2. Ndyomugyenyi R. The burden of onchocerciasis in Uganda. Ann Trop Med Parasitol. 1998;92(1):133-137.
3. Raybould JN, White GB. The distribution, bionomics and control of onchocerciasis vectors (Diptera: Simuliidae) in Eastern Africa and the Yemen. Tropenmed Parasitol. 1979;30(4):505-547.
4. World Health Organisation. Onchocerciasis and its control. Technical report series No 852. Available from: http://www.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan=1&codcol=10&codcch=852. Accessed September 20, 2011.
5. Amazigo U, Noma M, Bump J, et al. Chapter 15. Onchocerciasis -Disease and Mortality in Sub-Saharan Africa. 2nd ed. Washington, DC: World Bank 2006-NCBI Bookshelf. Bookshelf ID: NBK2287 PMID: 21290648. pp. 1-11.
6. World Health Organisation. Technical report series No 752. Geneva 1987.
7. Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of cutaneous changes in onchocerciasis. Br J Dermatol. 1993;129(3):260-269.
8. Newland HS, White AT, Greene BM, Murphy RP, Taylor HR. Ocular manifestations of onchocerciasis in a rain forest area of west Africa. Br J Ophthalmol. 1991;75(3):163-169.
9. Thylefors B, Tonjum AM. Visual field defects in onchocerciasis. Br J Ophthalmol. 1978;62(7):462-467.
10. Eezzuduemhoi DR, Wilson D, Sheppard JD Jr, et al. Ophthalmologic Manifestations of Onchocerciasis. Available at: http://emedicine.medscape.com/article/1204593-overview. Accessed July 17, 2011.
11. Thylefors B. Ocular onchocerciasis. Bull World Health Organ. 1978;56(1):63-73.
12. McKechnie NM, Braun G, Kläger S, et al. Cross-reactive antigens in the pathogenesis of onchocerciasis. Ann Trop Med Parasitol. 1993;87(6):649-652.
13. Van der Lelij A, Doekes G, Hwan BS, et al. Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis. Invest Ophthalmol Vis Sci. 1990;31(7):1374-1380.
14. Paganelli R, Ngu JL, and Levinsky RJ. Circulating immune complexes in onchocerciasis. Clin Exp Immunol. 1980;39(3):570-575.
15. Zahar AR. The ecology and distribution of black flies (Simulidae) in south-east Scotland. J Anim Ecol. 1951;20(1):33-62.
16. Le Berre R, Walsh JF, Philippon B, et al. The WHO Onchocerciasis Control programme: retrospect and prospects. Philos Trans R Soc Lond B Biol Sci. 1990;328(1251):721-729.
17. Hougard JM, Yaméogo L, Sékétéli A, Boatin B and Dadzie KY. Twenty-two years of blackfly control in the onchocerciasis control programme in West Africa. Parasitol Today. 1997;13(11): 425-431.
18. Guillet P, SeketeIi A, Alley ES, et al. Impact of combined largescale ivermectin distribution and vector control on transmission of Onchocerca volvulus in the Niger basin, Guinea. Bull World Health Organ. 1995;73(2):199-205.
19. Jamnback H. Recent developments in control of blackflies. Annu Rev Entomol. 1973;18:281-304.
20. Molyneux DH, Davies JB. Onchocerciasis control: Moving towards the millennium. Parasitol Today. 1997;13(11):418-425.
21. Prost A, Prescott N. Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta. Bull World Health Organ. 1984;62(5):795-802.
22. La Rocca RV, Danesi R, Cooper MR, et al. Effect of suramin on human prostate cancer cells in vitro. J Urol. 1991;145(2):393-398.
23. Anderson J, Fuglsang H. Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin. Br J Ophthalmol. 1978;62(7):450-457.
24. Kaur M, Reed E, Sartor D, Dahut W, Fizz WD. Suramin development: What did we learn? Invest New Drugs. 2002;20(2):209-219.
25. Anderson J, Fuglsang H, de C Marshall TF. Effects of suramin on ocular onchocerciasis. Tropenmed Parasitol. 1976;27(3):279-296.
26. Arlt W, Reincke M, Siekmann L, Winkelmann W, Allolio B. Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clin Endocrinol (Oxf). 1994;41(3):299-307.
27. Thylefors B, Rolland A. The risk of optic atrophy following suramin treatment of ocular onchocerciasis. Bull World Health Organ. 1979;57(3):479-480.
28. Francis H, Awadzi K, Ottesen EA. The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg. 1985; 34(3):529-536.
29. Stingl D, Stingl M. Leprosy, onchocerciasis, diethylcarbamazine and the Mazzotti reaction. Lepr Rev. 1982;53(4):317-318.
30. Bryceson AD. What happens when microfilariae die? Trans R Soc Trop Med Hyg. 1976;70(5-6):397-401.
31. Bryceson AD, Warrell DA, Pope HM. Dangerous reactions to treatment of onchocerciasis with diethylcarbamazine. Br Med J. 1977;1(6063):742-744.
32. Bird AC, el-Sheikh H, Anderson J, Fuglsang H. Changes in visual function in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. Br J Ophthalmol. 1980;64(3):191-200.
33. Guderian RH. Effects of nodulectomy in onchocerciasis in Ecuador. Trop Med Parasitol. 1988;39 Suppl 4:356-357.
34. The ivermectin story. Available at: http://www.satoshi-omura.info/ivermectin/ivermectin.html. Accessed July 16, 2011.
35. Omura S, Crump A. The life and times of ivermectin - a success story. Nat Rev Microbiol. 2004;2(12):984-989.
36. Abiose A, Jones BR, Cousens SN, et al. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet. 1993;341(8838):130-134.
37. Murdoch I, Abiose A, Babalola O, et al. Ivermectin and onchocercal optic neuritis: short-term effects. Eye (Lond). 1994;8(Pt 4): 456-461.
38. Pacqué M, Muñoz B, Greene BM, Taylor HR. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment. J Infect Dis. 1991;163(2):381-385.
39. Campbell WC, Benz GW. Ivermectin: a review of efficacy and safety. J Vet Pharmacol Ther. 1984;7(1):1-16.
40. Barragry RB. A review of the pharmacology and clinical uses of ivermectin. Can Vet J. 1987;28(8):512-517.
41. Burg RW, Miller BM, Baker EE, et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother. 1979;15(3):361-367.
42. Campbell WC, Fisher MH, Stapley EO, Albers-Schonberg G, Jacob TA. Ivermectin: a potent new antiparasitic agent. Science. 1983;221(4613):823-828.
43. Nolan J, Schnitzerling HJ, Bird P. Evaluation of the potential of systemic slow release chemical treatments for control of the cattle tick Boophilus microplus using ivermectin. Aust Vet J. 1981;57(11): 493-497.
44. McPherson WB, Cairns GC, Scott PC. Productivity studies with ivermectin in sheep and cattle in New Zealand. In: Leaning WHD, editor. Recent Developments in the Control of Animal Parasites. Proceedings of the MSD AGVET Symposium on Recent Developments in the Control of Animals Parasites, XXII World Veterinary Congress, Perth, Australia. 1983:174-191.
45. Anderson RR. The use of ivermectin in the horse-research and clinical observations. Compend Contin Educ Pract Vet. 1984;6:S516-S520.
46. Campbell WC, Blair LS. Efficacy of avermectin against Dirofilaria immitis in dogs. J Helminthol. 1978;52:308-310.
47. Blair LS, Campbell WC. Efficacy of ivermectin against Dirofilaria immitis larvae in dogs 31, 60 and 80 days after infection. Am J Vet Res. 1980;41(12):2108.
48. Fritz LC, Wang CC, Gorio A. Avermectin B1a irreversibly blocks post synaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance. Proc Natl Acad Sci U S A. 1979;76(4):2062-2066.
49. Mellin T, Busch RC, Wang CC. Postsynaptic inhibition of invertebrate neuromuscular transmissions by avermectin B1a. Neuropharmacology. 1983;22(1):89-96.
50. Pony SS, Wang CC. Avermectin B1a increases the number of GABA receptors in thoroughly washed rat brain membranes. Abstract presented at the 10th Annual Meeting of the Society for Neuroscience, Cincinnati, OH, June14-17, 1980.
51. Pony SS, Wang CC, Fritz LC. Studies on the mechanisms of action of avermectin B1a: stimulation of release of gamma amino butyric acid from brain synaptosomes. J Neurochem. 1980;34(2):351-358.
52. McCavera S, Rogers AT, Yates DM, Woods DJ, Wolstenholme AJ. An ivermectin-sensitive glutamate-gated chloride channel from the parasitic nematode Haemonchus contortus. Mol Pharmacol. 2009;75(6): 1347-1355.
53. Doss R. Ivermectin Toxicity Signs. 2009. Available at: http://www.livestrong.com/article/32684-ivermectin-toxicity-signs/. Accessed on October 13, 2011.
54. Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue, Duke BO. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet. 2002;360(9328):203-210.
55. ® Donation Program: 20 Years of Progress. Available at: http://www.merck.com/corporate-responsibility/docs/MDP-Backgrounder-2008.pdf. Accessed July 11, 2011.
56. Alexander ND, Cousens SN, Yahaya H, Abiose A, Jones BR. Ivermectin dose assessment without weighing scales. Bull World Health Organ. 1993;71(3-4):361-366.
57. Noma M, Nwoke BE, Nutall I, et al. Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96 Suppl 1:S29-S39.
58. APOC WEBSITE. Available at: http://www.who.int/apoc/cdti/projects/en/index.html. Accessed June 19, 2011.
59. Amazigo UV, Brieger WR, Katabarwa M, et al. The challenges of community-directed treatment with ivermectin (CDTI) within the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96 Suppl 1:S41-S58.
60. Brieger WR, Otusanya SA, Oke GA, Oshiname FO, Adeniyi JD. Factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria. Trop Med Int Health. 2002;7(1):11-18.
61. Katabarwa MN, Habomugisha P, Richards FO Jr. Implementing community-directed treatment with ivermectin for the control of onchocerciasis in Uganda (1997-2000): an evaluation. Ann Trop Med Parasitol. 2002;96(1):61-73.
62. Rothova A, Stilma JS, Van Der Lelij A, Wilson WR, Barbe RF. Side-effects of ivermectin in treatment of onchocerciasis. Lancet. 1989;1(8652):1439-1441.
63. Ottesen EA. Ivermectin in human Medicine. J Antimicrob Chemother. 1994;34(2):195-203.
64. Ivermectin Side Effects. Available at: http://www.drugs.com/sfx/ivermectin-side-effects.html. Accessed on October 10, 2011.
65. Oyibo WA, Fagbenro-Beyioku AF. Adverse reactions following annual ivermectin treatment of onchocerciasis in Nigeria. Int J Infect Dis. 2003;7(2):156-159.
66. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Jean-Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet. 1997;350(9070):18-22.
67. Borsboom G, Boatin B, Nagelkerke N, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J. 2003;2(1):8. Available at: http://www.filariajournal.com/content/2/1/8. Accessed July 7, 2011.
68. Dadzie Y, Neira M, Hopkins D. Final report of the Conference on the eradicability of Onchocerciasis. Filaria J. 2003;2(1):2.
69. Rodríguez-Pérez MA, Unnasch TR, Domínguez-Vázquez A, et al. Interruption of transmission of Onchocerca volvulus in the Oaxaca focus, Mexico. Am J Trop Med Hyg. 2010;83(1):21-27.
70. Murdoch ME. Onchodermatitis. Curr Opin Infect Dis. 2010;23(2): 124-131.
71. Diawara L, Traoré MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3(7):e497.
72. Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, Gyapong JO, Prichard RK. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011;5(3):e998.
73. Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety, tolerability and pharmacokinetics in humans. J Clin Pharmacol. 2003;43(10):1108-1115.
74. A suitable macrofilaricide? Available at: https://apps.who.int/tdr/publications/tdrnews/news62/moxidectin.htm. Accessed July 12, 2011.
75. A single-dose, ivermectin-controlled, double-blind, efficacy, safety and tolerability study of orally administered moxidectin in subjects infected with onchocerca volvulus. Available at: http://clinicaltrials.gov/ct2/show/NCT00790998. Accessed July 10, 2011.
76. N Siva. WHO researchers start trial on a new drug for river blindness - BMJ. BMJ. 2009;339:b2755. Available at: www.bmj.com/content/339/bmj.b2755.extract. Accessed on October 10, 2011.
77. Mackenzie CD, Geary TG. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs. Expert Rev Anti Infect Ther. 2011;9(5):497-501.
78. Dominguez-Vasquez A, Taylor HR, Greene BM, et al. Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. Lancet. 1983;1(8317):139-143.
79. Denham DA, Samad R, Cho SY, Suswillo RR, Skippins SC. The anthelmintic effects of flubendazole on Brugia pahangi. Trans R Soc Trop Med Hyg. 1979;73(6):673-676.
80. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrin in drug delivery: an updated review. AAPS PharmSciTech. 2005;6(2):E329-E357.
81. Ceballos L, Elissondo M, Bruni SS, Denegri G, Alvarez L, Lanusse C. Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice. Parasitol Int. 2009;58(4):354-358.
82. Death to Onchocerciasis and Lymphatic Filariasis [hompage]. Available at: http://www.dolf.wustl.edu/. Accessed June 24, 2011.
83. Mectizan and Albendazole for LF. Available at: http://www.mectizan.org/mectizan-albendazole-lf. Accessed July 12, 2011.
84. Awadzi K, Hero M, Opoku NO, et al. The chemotherapy of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pre-treatment with ivermectin on drug response and pharmacokinetics. Trop Med Parasitol. 1994;45(3):203-208.
85. Bockarie MJ, Deb RM. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Curr Opin Infect Dis. 2010;23(6): 617-620.
86. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet. 2000;355(9211):1242-1243.
87. Wu B, Novelli J, Foster J, et al. The heme biosynthetic pathway of the obligate wolbachia endosymbiont of brugia malayi as a potential anti-filarial drug target. PLos open access library. Available at: http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000475. Accessed July 20, 2011.
88. Taylor MJ, Hoerauf A, Bockarie M. Lymphatic filariasis and onchocerciasis. Lancet. 2010;376(9747):1175-1185.
89. Slatko BE, Taylor MJ, Foster JM. The Wolbachia endosymbiont as an anti-filarial nematode target. Symbiosis. 2010;51(1):55-65.
90. Hoerauf A, Mand S, Volkmann L, et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect. 2003;5(4)261-273.
91. Filarial worms Database. Available at: http://www.broadinstitute.org/annotation/genome/filarial_worms/MultiHome.html. Accessed July 17, 2011.
92. Darben P. The filarial nematodes. 1997 [updated January 31, 2002]. Available at: http://home.austarnet.com.au/~wormman/WLNEMA1.HTM. Accessed on October 8, 2011.
93. Filariasis. Available at: http://www.who.int/topics/filariasis/en/ Accessed July 17, 2011.
94. Brieger WR, Awedoba AK, Eneanya CI, et al. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health. 1998;3(12):951-961.
95. Ozoh GA, Murdoch ME, Bissek AC, et al. The African Programme for Onchocerciasis Control: impact on onchocercal skin disease. Trop Med Int Health. 2011;16(7):875-883.
96. African Programme for Onchocerciasis Control. Available at: http://www.who.int/apoc/publications/progress_report_jaf13_2007_en.pdf. Accessed July 7, 2011.
97. Onchocerciasis control partners' meeting. A strategic overview of the future of onchocerciasis control in Africa. WHO/APOC; 2006. Available at: http://www.who.int/apoc/publications/final_report_of_the_working_group_en.pdf. Accessed July 7, 2011.
98. Abiose A. Onchocercal eye disease and the impact of Mectizan treatment. Ann Trop Med Parasitol. 1998;92 Suppl 1:S11-S22.
99. Cousens SN, Cassels-Brown A, Murdoch I, et al. Impact of annual dosing with ivermectin on progression of onchocercal visual field loss. Bull World Health Organ. 1997;75(3):229-236.
100. Ejere H, Schwartz E, Wormald R. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database Syst Rev. 2001;(1):CD002219.
101. ®) on the prevalence and morbidity of onchocerciasis in the village of Gami in the Central African Republic. Ann Trop Med Parasitol. 2002;96(3):297-307.